CCRCC
MCID: RNL003
MIFTS: 54

Renal Clear Cell Carcinoma (CCRCC) malady

Categories: Nephrological diseases, Rare diseases, Cancer diseases, Genetic diseases

Aliases & Classifications for Renal Clear Cell Carcinoma

Aliases & Descriptions for Renal Clear Cell Carcinoma:

Name: Renal Clear Cell Carcinoma 12 52 14
Clear-Cell Metastatic Renal Cell Carcinoma 12 69
Conventional Renal Cell Carcinoma 12 69
Clear Cell Renal Carcinoma 56 29
Clear Cell Renal Cell Adenocarcinoma 56
Conventional Renal Cell Carcinoma 12
Clear Cell Renal Cell Carcinoma 56
Clear Cell Carcinoma of Kidney 12
Clear Cell Kidney Carcinoma 12
Ccrcc 56

Classifications:

Orphanet: 56  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4467
MeSH 42 D002292
NCIt 47 C4033
Orphanet 56 ORPHA319276
ICD10 via Orphanet 34 C64
UMLS 69 C0279702

Summaries for Renal Clear Cell Carcinoma

Disease Ontology : 12 A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

MalaCards based summary : Renal Clear Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to multinodular goiter and hereditary conventional renal cell carcinoma, and has symptoms including flank pain An important gene associated with Renal Clear Cell Carcinoma is VHL (Von Hippel-Lindau Tumor Suppressor), and among its related pathways/superpathways are Innate Immune System and Cellular Senescence. The drugs Sunitinib and Axitinib have been mentioned in the context of this disorder. Affiliated tissues include kidney, thyroid and lung, and related phenotypes are Increased Nanog expression and hematopoietic system

Related Diseases for Renal Clear Cell Carcinoma

Diseases in the Renal Cell Carcinoma family:

Hereditary Renal Cell Carcinoma Renal Clear Cell Carcinoma
Renal Cell Carcinoma 4

Diseases related to Renal Clear Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
id Related Disease Score Top Affiliating Genes
1 multinodular goiter 29.8 KDR MTOR VEGFA
2 hereditary conventional renal cell carcinoma 12.1
3 clear cell renal cell carcinoma 11.5
4 gtp cyclohydrolase 1-deficient dopa-responsive dystonia 10.3 HIF1A VHL
5 kidney osteogenic sarcoma 10.3 KDR VEGFA
6 neuropathy with hearing impairment 10.2 KDR VEGFA VHL
7 hole retinal cyst 10.2 CA9 HIF1A KDR
8 acute posterior multifocal placoid pigment epitheliopathy 10.2 HIF1A VEGFA VHL
9 oppositional defiant disorder 10.2 HIF1A KDR VEGFA
10 endocervicitis 10.2 BIRC5 HIF1A VEGFA
11 thyroiditis 10.2
12 central nervous system embryonal carcinoma 10.2 HIF1A MUC1
13 erythrocytosis, familial, 2 10.2 HIF1A VEGFA VHL
14 factitious disorder 10.2 KDR MME VEGFA
15 sacrococcygeal teratoma 10.2 HIF1A SETD2 VEGFA
16 albinism, oculocutaneous, type ib 10.2 HIF1A KDR VEGFA
17 motor neuron disease 10.2 MUC1 VHL
18 granular cell leiomyosarcoma 10.2 MUC1 VEGFA VHL
19 isolated anterior cervical hypertrichosis 10.2 HIF1A VEGFA VIM
20 myoma 10.2 MUC1 VIM
21 aniridia - ptosis - intellectual disability - familial obesity 10.1 KDR MME
22 central nervous system leiomyosarcoma 10.1 CA9 HIF1A VEGFA VHL
23 vulvar proximal-type epithelioid sarcoma 10.1 BIRC5 MUC1 VEGFA
24 spleen angiosarcoma 10.1 MUC1 VIM
25 subependymal glioma 10.1 KDR MUC1 VIM
26 coronary stenosis 10.1 MUC1 VEGFA VIM
27 immunodeficiency due to a classical component pathway complement deficiency 10.1 BIRC5 MUC1 VIM
28 marfanoid hypermobility syndrome 10.1 MUC1 VIM
29 lymphangiosarcoma 10.1 MME MUC1 VIM
30 sebaceous adenoma 10.1 MME MUC1 VIM
31 autosomal recessive stickler syndrome 10.1 MUC1 VIM
32 catastrophic antiphospholipid syndrome 10.1 TMEM127 VHL
33 acrocapitofemoral dysplasia 10.1 TMEM127 VHL
34 biliary papillomatosis 10.1 MUC1 VIM
35 testicular cancer 10.1 BIRC5 KDR MUC1 VEGFA
36 bone ameloblastoma 10.1 TMEM127 VHL
37 human granulocytic anaplasmosis 10.0 KDR MUC1 VEGFA VIM
38 hypoxia 10.0
39 kidney benign neoplasm 10.0 BIRC5 MUC1 VEGFA VIM
40 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 10.0 MUC1 VIM
41 pericardial mesothelioma 10.0 MUC1 PBRM1 VIM
42 generalized eruptive keratoacanthoma 10.0 CA9 MME PBRM1 VHL
43 thanatophoric dysplasia, type ii 10.0 BIRC5 CA9 FHIT HIF1A
44 hypogonadotropic hypogonadism 20 with or without anosmia 10.0 CA9 FHIT HIF1A VEGFA
45 mini stroke 10.0 CA9 HIF1A MTOR VEGFA VHL
46 microinvasive cervical squamous cell carcinoma 9.9 MUC1 VIM
47 renal cell carcinoma 9.9
48 adenocarcinoma 9.8
49 pancreatitis 9.8
50 cardiomyopathy, dilated, 1h 9.8 BIRC5 HIF1A KDR MME MTOR VEGFA

Graphical network of the top 20 diseases related to Renal Clear Cell Carcinoma:



Diseases related to Renal Clear Cell Carcinoma

Symptoms & Phenotypes for Renal Clear Cell Carcinoma

UMLS symptoms related to Renal Clear Cell Carcinoma:


flank pain

GenomeRNAi Phenotypes related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.78 VEGFA BIRC5 ELOB SETD2
2 Increased Nanog expression GR00371-A-2 9.78 VEGFA SETD2 VHL
3 Increased Nanog expression GR00371-A-3 9.78 BIRC5
4 Increased Nanog expression GR00371-A-4 9.78 VEGFA SETD2
5 Increased Nanog expression GR00371-A-5 9.78 VEGFA BIRC5 ELOB MTOR SETD2 VHL

MGI Mouse Phenotypes related to Renal Clear Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 HIF1A KDR MTOR PBRM1 SETD2 VEGFA
2 embryo MP:0005380 10.02 BIRC5 HIF1A KDR MTOR PBRM1 SETD2
3 cardiovascular system MP:0005385 10.01 HIF1A KDR MTOR PBRM1 SETD2 VEGFA
4 homeostasis/metabolism MP:0005376 10 VHL VIM BIRC5 FHIT HIF1A KDR
5 immune system MP:0005387 9.9 BIRC5 CA9 FHIT HIF1A KDR MME
6 liver/biliary system MP:0005370 9.43 PBRM1 VEGFA VHL HIF1A KDR MME
7 mortality/aging MP:0010768 9.36 BIRC5 CA9 FHIT HIF1A KDR MTOR

Drugs & Therapeutics for Renal Clear Cell Carcinoma

Drugs for Renal Clear Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
2
Axitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 319460-85-0 6450551
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
4
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
5
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1 946414-94-4
6 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
7 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
13 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
21
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
22
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
23
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
24
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
26
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
27
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
28
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
29
Paclitaxel Approved, Vet_approved Phase 3,Phase 1 33069-62-4 36314
30
Morphine Approved, Investigational Phase 3 57-27-2 5288826
31
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
32
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
33
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
34
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
35
Sulfamethoxazole Approved Phase 3 723-46-6 5329
36
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
37
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
39
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
40
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
41
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 59-67-6 938
42
Nicotinamide Approved, Nutraceutical Phase 3,Phase 1,Phase 2 98-92-0 936
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
44
Doxil Approved June 1999 Phase 3,Phase 2 31703
45 interferons Phase 3,Phase 2,Phase 1
46 Alkylating Agents Phase 3,Phase 2,Phase 1
47 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
48 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
50 Etoposide phosphate Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 270)
id Name Status NCT ID Phase
1 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
2 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4
3 Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors Recruiting NCT02700568 Phase 4
4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Recruiting NCT02982954 Phase 4
5 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Recruiting NCT01521715 Phase 4
6 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4
7 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4
8 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3
9 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
10 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3
11 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
12 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
13 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3
14 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3
15 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3
16 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
18 Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Completed NCT00678392 Phase 3
19 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
20 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
21 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
22 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
23 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Recruiting NCT02883153 Phase 2, Phase 3
24 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Recruiting NCT01575548 Phase 3
25 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Recruiting NCT02535351 Phase 3
26 Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Recruiting NCT03055013 Phase 3
27 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Recruiting NCT02928692 Phase 3
28 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Active, not recruiting NCT01668784 Phase 3
29 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Active, not recruiting NCT01599754 Phase 3
30 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01099423 Phase 3
31 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Active, not recruiting NCT01198158 Phase 3
32 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3
33 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Not yet recruiting NCT01762592 Phase 3
34 Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Not yet recruiting NCT03142334 Phase 3
35 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Unknown status NCT01069770 Phase 2
36 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2
37 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Unknown status NCT01216371 Phase 2
38 Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery Unknown status NCT00293501 Phase 1, Phase 2
39 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status NCT00301990 Phase 2
40 Immunochemotherapy for Metastatic Renal Cell Carcinoma Unknown status NCT00226798 Phase 2
41 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2
42 A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy Unknown status NCT01693822 Phase 2
43 Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer Unknown status NCT01784978 Phase 2
44 Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients Unknown status NCT02324803 Phase 2
45 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2
46 Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2
47 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2
48 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
49 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma Completed NCT00729053 Phase 2
50 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Completed NCT01034631 Phase 1, Phase 2

Search NIH Clinical Center for Renal Clear Cell Carcinoma

Genetic Tests for Renal Clear Cell Carcinoma

Genetic tests related to Renal Clear Cell Carcinoma:

id Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 29

Anatomical Context for Renal Clear Cell Carcinoma

MalaCards organs/tissues related to Renal Clear Cell Carcinoma:

39
Kidney, Thyroid, Lung, Tongue, Salivary Gland, Endothelial, Liver

Publications for Renal Clear Cell Carcinoma

Articles related to Renal Clear Cell Carcinoma:

(show top 50) (show all 158)
id Title Authors Year
1
Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes: A case report. ( 28072710 )
2017
2
Monoexponential, biexponential, and stretched exponential diffusion-weighted imaging models: Quantitative biomarkers for differentiating renal clear cell carcinoma and minimal fat angiomyolipoma. ( 27859853 )
2016
3
PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma. ( 27100670 )
2016
4
Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma. ( 26909952 )
2016
5
Analysis of distribution of DNA methylation in kidney-renal-clear-cell-carcinoma specific genes using entropy. ( 27818943 )
2016
6
Identifying prognostic biomarkers based on aberrant DNA methylation in kidney renal clear cell carcinoma. ( 28029655 )
2016
7
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. ( 27484998 )
2016
8
Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma. ( 27110129 )
2016
9
Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma. ( 26992212 )
2016
10
Renal clear cell carcinoma metastasis to salivary glands - a series of 9 cases: clinico-pathological study. ( 27179273 )
2016
11
Unusual Ultrasound Presentation of Testicular Metastasis from Renal Clear Cell Carcinoma. ( 27746886 )
2016
12
Screening for the Key lncRNA Targets Associated With Metastasis of Renal Clear Cell Carcinoma. ( 26765468 )
2016
13
Prognostic and Predictive Values of Subcellular Localisation of RET in Renal Clear-Cell Carcinoma. ( 27092013 )
2016
14
Tubular epithelial cells in renal clear cell carcinoma express high RIPK1/3 and show increased susceptibility to TNF receptor 1-induced necroptosis. ( 27362805 )
2016
15
Clinical significance of changes of expression of the Wnt/I^-catenin signaling pathway in renal clear cell carcinoma. ( 27981554 )
2016
16
Metastases of renal clear cell carcinoma to ovary--case report and review of the literature. ( 26050366 )
2015
17
microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes. ( 25758424 )
2015
18
Allicin inhibits human renal clear cell carcinoma progression via suppressing HIF pathway. ( 26884975 )
2015
19
An atypical metastasis of renal clear cell carcinoma to the upper lip: a case report. ( 25579020 )
2015
20
Image of the month: Gastric metastasis of renal clear cell carcinoma. ( 25713859 )
2015
21
Netrin-1: The new tumor markers in renal clear cell carcinoma. ( 26194836 )
2015
22
Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-I_B signaling in human renal clear cell carcinoma. ( 26617834 )
2015
23
Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma. ( 25592567 )
2015
24
Renal Clear Cell Carcinoma Acrometastasis. An Unusual Terminal Condition. ( 26078530 )
2015
25
Differentiation of renal oncocytoma and renal clear cell carcinoma using relative CT enhancement ratio. ( 25591558 )
2015
26
A Five-Gene Signature Predicts Prognosis in Patients with Kidney Renal Clear Cell Carcinoma. ( 26539246 )
2015
27
Expression and Prognostic Role of MEKK3 and pERK in Patients with Renal Clear Cell Carcinoma. ( 25824786 )
2015
28
A unique presentation of a renal clear cell carcinoma with atypical metastases. ( 25911241 )
2015
29
Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. ( 26506913 )
2015
30
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. ( 26312386 )
2015
31
Bilateral sporadic synchronous renal clear-cell carcinoma treated by bilateral partial laparoscopic nephrectomy: Report of two cases. ( 26530869 )
2015
32
Renal clear cell carcinoma with thyroid and parotid metastases: A case report. ( 26622899 )
2015
33
High selectivity of PI3KI^ inhibitors in SETD2-mutated renal clear cell carcinoma. ( 26537074 )
2015
34
Expression of PGAM1 in renal clear cell carcinoma and its clinical significance. ( 26464696 )
2015
35
Expression and significance of FOXP1, HIF-1a and VEGF in renal clear cell carcinoma. ( 25778315 )
2015
36
Loss of MLH1 confers resistance to PI3KI^ inhibitors in renal clear cell carcinoma with SETD2 mutation. ( 25528216 )
2014
37
An easy model for prediction of human renal clear cell carcinoma: curve fitting for three kidney tumors observed for over 10 years. ( 24534241 )
2014
38
The Expression and Role of MEKK3 in Renal Clear Cell Carcinoma. ( 25388155 )
2014
39
Liquid chromatography-mass spectrometry based serum peptidomic approach for renal clear cell carcinoma diagnosis. ( 25168216 )
2014
40
Protein interactions of cortactin in relation to invadopodia formation in metastatic renal clear cell carcinoma. ( 25527159 )
2014
41
Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. ( 24454902 )
2014
42
A Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib. ( 24707294 )
2014
43
Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma. ( 25027579 )
2014
44
Simultaneous bilateral testicular metastases from renal clear cell carcinoma: A case report and review of the literature. ( 24944706 )
2014
45
An unusual case of metastatic renal clear cell carcinoma presented as a solitary subcutaneous mass invading the manubrium. ( 25024354 )
2014
46
Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity. ( 25648588 )
2014
47
Identification of angiogenesis-related miRNAs in a population of patients with renal clear cell carcinoma. ( 25119741 )
2014
48
Neoadjuvant sunitinib effectiveness in T4 renal clear cell carcinoma: a case report. ( 25050998 )
2014
49
Identification of genes and pathways involved in kidney renal clear cell carcinoma. ( 25559354 )
2014
50
Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma. ( 24564989 )
2013

Variations for Renal Clear Cell Carcinoma

ClinVar genetic disease variations for Renal Clear Cell Carcinoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh37 Chromosome 3, 9792107: 9792107
2 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh37 Chromosome 12, 121432125: 121432125
3 HNF1A NM_000545.6(HNF1A): c.92G> A (p.Gly31Asp) single nucleotide variant Pathogenic rs137853247 GRCh37 Chromosome 12, 121416663: 121416663
4 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh37 Chromosome 3, 52597380: 52597387

Cosmic variations for Renal Clear Cell Carcinoma:

9 (show top 50) (show all 981)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 18
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 18
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 18
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 18
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 18
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 18
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 18
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 18
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 18
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 18
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 18
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 18
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 18
14 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 13
15 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 13
16 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 13
17 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 13
18 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 13
19 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 13
20 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 13
21 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 13
22 COSM30715 WISP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.868T>C p.C290R 13
23 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13
24 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13
25 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 13
26 COSM14400 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>T p.S65L 13
27 COSM30293 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.586A>T p.K196* 13
28 COSM17734 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.304C>G p.P102A 13
29 COSM36358 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.341-11T>A p.? 13
30 COSM17658 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 13
31 COSM34007 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.227T>C p.F76S 13
32 COSM249280 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.264G>A p.W88* 13
33 COSM18023 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.486C>G p.C162W 13
34 COSM17875 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.234T>G p.N78K 13
35 COSM30212 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.202T>C p.S68P 13
36 COSM18276 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.406T>G p.F136V 13
37 COSM14407 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>C p.V130L 13
38 COSM18212 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.491A>C p.Q164P 13
39 COSM14311 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.499C>T p.R167W 13
40 COSM14380 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.548C>A p.S183* 13
41 COSM30295 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.341-2A>G p.? 13
42 COSM18015 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>A p.S65* 13
43 COSM18386 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.574C>T p.P192S 13
44 COSM18005 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.340+1G>A p.? 13
45 COSM17990 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463+2T>A p.? 13
46 COSM14397 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.490C>T p.Q164* 13
47 COSM17870 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.203C>T p.S68L 13
48 COSM17711 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.208G>T p.E70* 13
49 COSM30216 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.239G>A p.S80N 13
50 COSM3734682 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.280G>A p.E94K 13

Expression for Renal Clear Cell Carcinoma

Search GEO for disease gene expression data for Renal Clear Cell Carcinoma.

Pathways for Renal Clear Cell Carcinoma

Pathways related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 BIRC5 ELOB HIF1A MME MTOR MUC1
2
Show member pathways
12.96 CA9 ELOB HIF1A MTOR VEGFA VHL
3
Show member pathways
12.61 ELOB HIF1A MTOR VEGFA VHL
4 12.44 BIRC5 ELOB HIF1A MTOR VEGFA VHL
5 12.1 HIF1A KDR MTOR VEGFA
6 11.89 KDR VEGFA VIM
7 11.67 CA9 HIF1A KDR
8
Show member pathways
11.67 HIF1A KDR VEGFA VHL
9 11.61 BIRC5 HIF1A MUC1 VEGFA VIM
10 11.5 CA9 HIF1A VEGFA
11 11.36 BIRC5 HIF1A VEGFA
12 11.29 ELOB HIF1A VEGFA VHL
13 11.2 BIRC5 HIF1A VEGFA
14 11.02 ELOB HIF1A MTOR VEGFA VHL
15 10.99 HIF1A KDR VEGFA
16 10.81 VEGFA VHL
17 10.79 ELOB KDR VEGFA VHL
18
Show member pathways
10.77 KDR VEGFA
19 10.67 ELOB HIF1A VHL
20 10.5 HIF1A VEGFA

GO Terms for Renal Clear Cell Carcinoma

Cellular components related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 VCB complex GO:0030891 8.62 ELOB VHL

Biological processes related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 HIF1A MTOR VEGFA VIM
2 negative regulation of apoptotic process GO:0043066 9.8 BIRC5 HIF1A KDR VEGFA VHL
3 positive regulation of angiogenesis GO:0045766 9.71 HIF1A KDR VEGFA
4 angiogenesis GO:0001525 9.67 HIF1A KDR SETD2 VEGFA
5 cellular response to hypoxia GO:0071456 9.65 HIF1A MTOR VEGFA
6 positive regulation of neuroblast proliferation GO:0002052 9.57 HIF1A VEGFA
7 camera-type eye morphogenesis GO:0048593 9.56 HIF1A VEGFA
8 embryonic hemopoiesis GO:0035162 9.52 HIF1A KDR
9 cell migration involved in sprouting angiogenesis GO:0002042 9.51 KDR VEGFA
10 vasculogenesis GO:0001570 9.5 KDR SETD2 VEGFA
11 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.49 HIF1A VEGFA
12 growth GO:0040007 9.46 MTOR VEGFA
13 positive regulation of positive chemotaxis GO:0050927 9.43 KDR VEGFA
14 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.26 KDR VEGFA
15 positive regulation of endothelial cell proliferation GO:0001938 9.26 HIF1A KDR MTOR VEGFA
16 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.16 HIF1A VEGFA
17 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.02 CA9 ELOB HIF1A VEGFA VHL

Sources for Renal Clear Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....